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Conclusion: The data suggest that the HLA-G 14-pb Ins/Del
polymorphism may not play a relevant role in the susceptibilityto
hepatitis B infection. However, the association between this poly-
morphism and infection severity suggests an evidence of HLA-G
implication in hepatitis B infection progression.
http://dx.doi.org/10.1016/j.ijid.2014.03.1063
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Background: The safety of blood products is one of the major
problems concerned with the transfusion medicine. A deﬁnite haz-
ard of transmission of hepatitis B to recipients of blood screen
for Hepatitis B surface Antigen (HBsAg) when such donor is at
the ‘window phase’ exist. The possibility of achieving zero risk
of Transfusion Associated Hepatitis B Virus (TAHBV) infection is
highly dependent on DNA testing of all collected units of blood
before transfusion. This is not feasible in low income countries
including Nigeria due to cost. At present, HBsAg detection is the
only diagnostic screening test for HBV infection identiﬁcation in
the blood transfusion centers of Nigeria. Hepatitis B core IgM anti-
body (anti-HBc IgM) is gaining prominence as a useful alternative
in reducing TAHBV infection. The present study was aimed at eval-
uating adoption of anti-HBc IgM an additional screening assay
for blood donation since anti-HBc detection is not mandatory in
Nigeria.
Methods & Materials: Two hundred and seventy-three
(Male =246, F =27; Age range:18-50 Mean:24.9years) apparently
healthy blood donors in Ibadanwere enrolled in the study between
October andDecember2012; their demographicdatawasobtained.
The frequency of HBsAg and its corresponding antibody (HBsAb),
as well as Hepatitis B envelope antigen and its corresponding anti-
body (HBeAg and Ab) were assessed using standard enzyme link
Immunosorbent assay EELISA) technique. Anti-HBcIgM was also
assessed in donors negative or positive for HBsAg using same
method.
Results: The prevalence of anti-HBc IgM was 4.4%. Twelve (11
Males and 1 female) had anti-HBc IgM as the only marker of HBV
infection. Prevalence of HBsAg, HBsAb, HBeAg and HBeAb were
14(5.1%), 95(34.8%), 2(14.3%) and 3(21.4%) respectively.
Conclusion: The ﬁndings of the current study recommends that
all blood units should be tested for anti -HBc IgM to understand the
infectivity status of the blood donors in the window period and to
discardblood if zero risk of TransfusionAssociatedHepatitis BVirus
(TAHBV) infection will be achieved in Nigeria.
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Background: It is well known that long-term complications of
hepatitis C virus (HCV) infection including hepatocellular carci-
noma (HCC) and cirrhosis are eliminated or decrease in sustained
virological responders after treatment. We report a case from
Turkey who developed HCC 4 years after sustained and complete
response to pegylated interferon plus ribavirin combination ther-
aphy.
Methods & Materials: A 60-year-old man with HCV genotype
1b was treated with pegylated interferon alpha-2b in combination
with ribavirin for a total of 52weeks. Initially, his liverhistologywas
consistent with amild activity and 1\6 ﬁbrosis stage due to chronic
hepatitis C. After 28 weeks of treatment, aminotransferase levels
were in the normal range and HCV RNA (polymerase chain reac-
tion) was undetectable in serum. Sustained and complete response
were obtained with normalization of aminotransferases and dis-
appearance of HCV RNA in serum continuously. HCV-RNA was also
not detected in the liver tissue after treatment, but histopatholog-
ical examination was the same as before. He followed up for HCC
based on biochemical and ultrasound evaluation every 6 months.
Results: HCC was detected 48 months after cessation of
therapy with the elevation of serum aminotransferases and alpha-
fetoprotein for the ﬁrst time, then splenomegaly and acid were
revealed by ultrasonography. HCC was diagnosed by computed
tomography and angiography, and then treated through transarte-
rial embolization but patient died of liver failure within 2 months.
Conclusion: Successful treatment in our case didn’t prevent
development of HCC even in non-cirrhotic liver. Our case indicates
the importance of not underestimating risk of HCC development
even many years after sustained and complete response to HCV
treatment. Long-term follow up are always mandatory and should
include more carefully and closely surveillance for HCC.
http://dx.doi.org/10.1016/j.ijid.2014.03.1065
